Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | USP8 | P40818 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17529613 | 0.80 | CTSS (0.36) | NQO1HPGDSKDM4EMAPTALDH1A1 | |
| SCHEMBL17529647 | 0.80 | NQO1 (0.33) | NQO1KMT2A | |
| SCHEMBL19742933 | 0.75 | SOS2 (0.33) | NQO1SOS2 | |
| SCHEMBL4756829 | 0.74 | — | — | |
| SCHEMBL1638184 | 0.71 | — | — | |
| SCHEMBL315179 | 0.71 | POLB (0.33) | KDM4EKMT2AL3MBTL1TDP1POLB | |
| SCHEMBL1464459 | 0.71 | — | — | |
| SCHEMBL17529617 | 0.69 | — | — | |
| SCHEMBL17529634 | 0.69 | — | — | |
| SCHEMBL16741211 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2990404-B1 | TETRAZOLINONE COMPOUND AND USE OF SAME | SUMITOMO CHEMICAL CO (JP) | 2020-05-27 | — | — | EP | disclosed |
| EP-3029038-B1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2019-03-27 | — | — | EP | disclosed |
| EP-3112350-B1 | METHOD FOR PRODUCING PYRAZOLE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-9867372-B2 | Tetrazolinone compound and use of same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-01-16 | — | — | US | disclosed |
| US-9781933-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-10 | — | — | US | disclosed |
| US-9624177-B2 | Method for producing pyrazole compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-04-18 | — | — | US | disclosed |
| US-20170008853-A1 | METHOD FOR PRODUCING PYRAZOLE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-01-12 | — | — | US | disclosed |
| EP-3112350-A1 | METHOD FOR PRODUCING PYRAZOLE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-20160174558-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-23 | — | — | US | disclosed |
| EP-3029038-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | Sumitomo Chemical Company Limited (JP) | 2016-06-08 | — | — | EP | disclosed |
| US-20160081339-A1 | TETRAZOLINONE COMPOUND AND USE OF SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-03-24 | — | — | US | disclosed |
| EP-2990404-A1 | TETRAZOLINONE COMPOUND AND USE OF SAME | Sumitomo Chemical Company Limited (JP) | 2016-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008853-A1 | METHOD FOR PRODUCING PYRAZOLE COMPOUND | CBR3, POR, CBR1 | NQO1 61/4885HPGDS 515/4885KDM4E 4569/4885 |
| US-20160174558-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | MT-CO1, KCNA5, MT-CO2 | NQO1 711/4885HPGDS 4476/4885KDM4E 2475/4885 |
| US-20160081339-A1 | TETRAZOLINONE COMPOUND AND USE OF SAME | MT-CO1, SOD1, MT-CO2 | NQO1 541/4885HPGDS 4491/4885KDM4E 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.